China: Johnson & Johnson monopoly ruling hits several milestones for antitrust law
Johnson & Johnson became the first Fortune 500 company to be ruled a monopoly by a Chinese court, say reports. The decision reflects the nation’s strengthening position against price-fixing, say analysts. The verdict, delivered Thursday, ordered the US-based pharmaceutical giant to pay about $86,500 to an ex-dealer on which J&J imposed a price floor, said the Shanghai High People’s Court. The company forced minimum retail prices on its former China-based dealer Rainbow Medical. Chief judge Ding Wenlian said the medical instrument market in the nation has “faced a lack of competition. The ruling marks the first antitrust ruling in favor of the plaintiff, and the first vertical monopoly lawsuit in China since the establishment of the nation’s Anti-monopoly Law, which went into effect five years ago.
Featured News
Beumer Challenges EU Decision on Vanderlande-Siemens Merger Review
Jul 26, 2026 by
CPI
China Fines Trip.com US$765 Million in Major Antitrust Enforcement Action
Jul 26, 2026 by
CPI
House Judiciary Panel Launches Antitrust Inquiry Into Compass and MRED
Jul 26, 2026 by
CPI
Paramount Delays Warner Bros. Discovery Merger Until Antitrust Case Moves Forward
Jul 26, 2026 by
CPI
Judge Pushes Elite College Financial Aid Antitrust Trial Toward Thanksgiving Finish
Jul 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes